According to Zacks, “Neuronetics, Inc. is a commercial-stage medical device company. It focused on designing, developing, and marketing products for patients who suffer from psychiatric disorders. NeuroStar Advanced Therapy System(R), is the transcranial magnetic stimulation treatment for depressive disorder. Neuronetics, Inc. is based in Malvern, United States. “
A number of other analysts have also weighed in on STIM. Piper Jaffray Companies reduced their price target on shares of Neuronetics from $35.00 to $28.00 and set an “overweight” rating for the company in a research note on Tuesday, March 5th. BTIG Research reaffirmed a “buy” rating and issued a $25.00 price target on shares of Neuronetics in a research note on Wednesday, March 6th. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $31.60.
Neuronetics stock opened at $15.56 on Friday. The company has a quick ratio of 8.26, a current ratio of 8.44 and a debt-to-equity ratio of 0.43. The stock has a market cap of $283.58 million and a price-to-earnings ratio of -5.78. Neuronetics has a 52-week low of $13.26 and a 52-week high of $39.39.
Neuronetics (NASDAQ:STIM) last issued its quarterly earnings results on Tuesday, March 5th. The company reported ($0.35) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.01. The company had revenue of $15.64 million during the quarter, compared to analyst estimates of $14.71 million. Equities analysts forecast that Neuronetics will post -1.63 EPS for the current fiscal year.
In related news, VP Peter Donato sold 26,238 shares of the business’s stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $16.15, for a total value of $423,743.70. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Christopher Thatcher sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $16.82, for a total transaction of $252,300.00. The disclosure for this sale can be found here. Corporate insiders own 12.00% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Legal & General Group Plc bought a new stake in shares of Neuronetics in the 3rd quarter worth approximately $31,000. Advisor Group Inc. bought a new stake in shares of Neuronetics in the 4th quarter worth approximately $27,000. Bank of America Corp DE raised its holdings in shares of Neuronetics by 967.7% in the 4th quarter. Bank of America Corp DE now owns 5,787 shares of the company’s stock worth $111,000 after purchasing an additional 5,245 shares in the last quarter. New York State Common Retirement Fund bought a new stake in shares of Neuronetics in the 4th quarter worth approximately $122,000. Finally, Teachers Advisors LLC bought a new stake in shares of Neuronetics in the 3rd quarter worth approximately $267,000. Institutional investors and hedge funds own 68.71% of the company’s stock.
Neuronetics Company Profile
Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States, Japan, and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.
Featured Article: Why is the conference call important?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.